Cargando…
Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐censored toxicity endpoints with competing disease progression
The growing interest in new classes of anti‐cancer agents, such as molecularly‐targeted therapies and immunotherapies with modes of action different from those of cytotoxic chemotherapies, has changed the dose‐finding paradigm. In this setting, the observation of late‐onset toxicity endpoints may be...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691552/ https://www.ncbi.nlm.nih.gov/pubmed/36259523 http://dx.doi.org/10.1002/sim.9591 |